195 related articles for article (PubMed ID: 33177346)
1. Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea.
Black CJ; Ford AC
Am J Gastroenterol; 2021 Feb; 116(2):428-429. PubMed ID: 33177346
[No Abstract] [Full Text] [Related]
2. Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation?
Melchior C; Simrén M
Am J Gastroenterol; 2020 Dec; 115(12):1976-1978. PubMed ID: 33079746
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron and irritable bowel syndrome.
Luthra P; Ford AC
Gut; 2015 Jul; 64(7):1181. PubMed ID: 24846912
[No Abstract] [Full Text] [Related]
4. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
Plasse TF; Barton G; Davidson E; Abramson D; Kalfus I; Fathi R; Raday G; Harris MS
Am J Gastroenterol; 2020 Sep; 115(9):1466-1473. PubMed ID: 32639235
[TBL] [Abstract][Full Text] [Related]
5. The fall and rise of 5-hydroxytryptamine receptor antagonists in irritable bowel syndrome with diarrhea.
Luthra P; Ford AC
Gastroenterology; 2014 Aug; 147(2):527-8. PubMed ID: 24953627
[No Abstract] [Full Text] [Related]
6. An antiemetic for irritable bowel syndrome?
Levy R; Corbo J; Prasad S
J Fam Pract; 2014 Oct; 63(10):600-2. PubMed ID: 25343149
[TBL] [Abstract][Full Text] [Related]
7. Revival of 5-HT3 antagonism as treatment of IBS-D?
Barbara G
Gut; 2014 Oct; 63(10):1530-2. PubMed ID: 24465028
[No Abstract] [Full Text] [Related]
8. Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging.
Marciani L; Wright J; Foley S; Hoad CL; Totman JJ; Bush D; Hartley C; Armstrong A; Manby P; Blackshaw E; Perkins AC; Gowland PA; Spiller RC
Aliment Pharmacol Ther; 2010 Sep; 32(5):655-63. PubMed ID: 20626735
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
[TBL] [Abstract][Full Text] [Related]
10. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
11. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S
Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing Re-evaluation of Tongxiening Granules () in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial.
Tang XD; Zhang SS; Hou XH; Li ZH; Chen SN; Feng PM; Yang XN; Li HZ; Wu JQ; Xia PJ; Yang XJ; Zhou HJ; Wang HY; Ai YW; Li K
Chin J Integr Med; 2019 Dec; 25(12):887-894. PubMed ID: 31292845
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of Actimel for patients with the irritated bowel syndrome with prevailing diarrhea].
Parfenov AI; Ruchkina IN; Tsaregorodtsev TM; Serova TI
Eksp Klin Gastroenterol; 2005; (5):45-52. PubMed ID: 16518915
[No Abstract] [Full Text] [Related]
14. Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: a prospective, randomized, double-blind, placebo-controlled trial.
Wang G; Li TQ; Wang L; Xia Q; Chang J; Zhang Y; Wan MH; Guo J; Cheng Y; Huang X; Zhang RM
Chin Med J (Engl); 2006 Dec; 119(24):2114-9. PubMed ID: 17199964
[No Abstract] [Full Text] [Related]
15. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
16. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
Dizdar V; Gilja OH; Hausken T
Neurogastroenterol Motil; 2007 Dec; 19(12):977-82. PubMed ID: 17973637
[TBL] [Abstract][Full Text] [Related]
17. Zinc Deficiency and Intestinal Permeability in the Context of Rational Diagnostic and Drug Development for Diarrhea-Predominant Irritable Bowel Syndrome.
Shah ED
Dig Dis Sci; 2022 Aug; 67(8):3477-3478. PubMed ID: 35018534
[No Abstract] [Full Text] [Related]
18. Drugs for Irritable Bowel Syndrome.
Med Lett Drugs Ther; 2020 Mar; 62(1594):25-32. PubMed ID: 32324172
[No Abstract] [Full Text] [Related]
19. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
Mangel AW; Chaturvedi P
Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
[TBL] [Abstract][Full Text] [Related]
20. Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
Grover M; Camilleri M
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):960-2. PubMed ID: 24393804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
